An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers
Auteur Abdullah S Madhun
Auteur Per Espen Akselsen
Auteur Haakon Sjursen
Auteur Gabriel Pedersen
Auteur Signe Svindland
Auteur Jane Kristin Nøstbakken
Auteur Mona Nilsen
Auteur Kristin Mohn
Auteur Asne Jul-Larsen
Auteur Ingrid Smith
Auteur Diane Major
Auteur John Wood
Auteur Rebecca J Cox
Résumé Mass vaccination was the most effective prophylaxis for protecting the population during the influenza H1N1 pandemic. We have evaluated the tolerability, immunogenicity and kinetics of the antibody response to a monovalent oil-in-water (AS03) adjuvanted human pandemic split influenza A/California/7/2009 H1N1 (3.75μg haemagglutinin) vaccine in health care workers. Vaccination elicited a rapid and early protective level of haemagglutination inhibition antibody from 6 to 7 days post vaccination, and by 14 to 21 days post vaccination, up to 98% of vaccinees had protective antibody titres which persisted for at least 3 months in 84-92% of subjects. A rapid induction of protective antibody is important in reducing community spread of pandemic influenza and in helping maintain the integrity of the health care system during the pandemic.
Publication Vaccine
Date Oct 26, 2010
Chercher cette référence sur : Google Scholar, Worldcat
doi:10.1016/j.vaccine.2010.10.038
Laisser une réponse
Vous devez etre connectez Pour poster un commentaire